摘要
目的探讨G蛋白β3亚单位基因C825T多态性与氨氯地平降压疗效的关系。方法采用多聚酶链式反应结合限制性内切酶片段长度多态分析方法,检测147例健康人和321例原发性高血压患者的G蛋白β3亚单位C825T多态性,其中48例高血压患者口服氨氯地平4周。结果1)高血压组G蛋白β3亚单位C825T多态性中基因型频率(CC 28.7%、CT52.0%、TT 19.3%)、等位基因频率(C 54.7%、T 45.3%)与正常对照组基因型频率(CC 27.2%、CT 46.9%、TT 25.9%)、等位基因频率(C 50.7%、T 49.3%)比较差异无统计学意义;2)CC基因型的收缩压降低值〔(4.93±2.26)kPa(37.00±16.97)mmHg〕明显高于CT+TT基因型〔(2.99±1.41)kPa(22.40±10.60)mmHg〕(P<0.05)。结论G蛋白β3亚单位基因C825T多态性与氨氯地平的降压疗效相关,而与原发性高血压无关。
Objective To investigate the relationship between G protein β3 subunit gene polymorphism and the efficacy of antihypertensive treatment with amlodipine. Methods Polymerase chain reaction combined with restriction enzyme digestion was used to detect the polymorphism of G protein β3 subunit gene in 147 individuals as normotensive control and 321 hypertensive patients. 48 hypertensive patients were treated with amlodipine for 4 weeks. Results 1 ） There were no significant differences of the GNB3 gene C825T polymorphism genotypes and alleles between hypertensive patients （CC 28.7%, CT 52.0%, TT 19.3% （C 54.7%, T 45.3%） and normotensive controls （CC 27.2%, CT 46.9%, TT 25.9%, C 50.7%, T 49.3%）. Mean reduction in systolic blood pressure were significantly greater in CC genotype[ （4.93 ± 2.26）kPa（37.00 ± 16.97）mmHg] than in CT ± TT genotype[ （2.99 ± 1.41）kPa（22.40 ± 10.60）mmHg] （P〈0.05）. Conclusion The C825T polymorphism of G protein β3 subunit is related to the efficacy of amlodipine but not to essential hypertension.
出处
《首都医科大学学报》
CAS
2005年第6期725-728,共4页
Journal of Capital Medical University
基金
首都医学发展基金(20022007)资助项目
